Diabetologia

Papers
(The H4-Index of Diabetologia is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Branding foods as ‘healthy’ or ‘unhealthy’ based on marginal data calls findings into question. Reply to Kanter M [letter]675
Up Front405
Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study202
In Memoriam Werner Waldhäusl, 27 September 1937–22 May 2025176
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities171
Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory150
The SWI/SNF chromatin remodelling complex regulates pancreatic endocrine cell expansion and differentiation in mice in vivo127
Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes126
Critical comments regarding the assessment of quality of life and the clinical impact of the POWER2DM intervention. Reply to Pouwer F, Deschênes SS [letter]118
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes111
Birthweight, BMI in adulthood and latent autoimmune diabetes in adults: a Mendelian randomisation study110
Determination of autoantibodies in type 2 diabetes: one simple way to improve classification108
TBC1D30 regulates proinsulin and insulin secretion and is the target of a genomic association signal for proinsulin94
Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study90
60th EASD Annual Meeting of the European Association for the Study of Diabetes89
Methodological considerations for interpreting long-term statin use and diabetes incidence88
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection87
Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative86
Paediatric diabetes subtypes in a consanguineous population: a single-centre cohort study from Kurdistan, Iraq86
Cardiovascular risk management among individuals with type 2 diabetes and severe mental illness: a cohort study85
Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes81
The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT)81
Impact of normoglycaemia and prediabetes definitions on the estimated benefits of regression from prediabetes to normoglycaemia for type 2 diabetes risk78
Ageing well with diabetes: the role of technology76
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care75
Scientists and scientific journals should adhere to ethical standards for the use and reporting of data from Indigenous people74
Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study74
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy73
Sex-dependent intra-islet structural rearrangements affecting alpha-to-beta cell interactions lead to adaptive enhancements of Ca2+ dynamics in prediabetic beta cells72
Embracing complexity: making sense of diet, nutrition, obesity and type 2 diabetes68
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials67
Loneliness increases the risk of type 2 diabetes: a 20 year follow-up – results from the HUNT study67
58th EASD Annual Meeting of the European Association for the Study of Diabetes67
Heterotypic macrophages/microglia differentially contribute to retinal ischaemia and neovascularisation66
A simple score-based strategy to improve equity of the UK biennial diabetic eye screening protocol among people deemed as low risk66
Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open65
eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes65
Up Front65
Daniel Porte Jr, 13 August 1931–13 May 202365
Effects of progressive resistance training in individuals with type 2 diabetic polyneuropathy: a randomised assessor-blinded controlled trial65
Pinpointing precision medicine for diabetes mellitus63
Reassessing the evidence: prandial state dictates glycaemic responses to exercise in individuals with type 1 diabetes to a greater extent than intensity62
Adverse pregnancy outcomes in women with type 1 diabetes are associated with multiple alterations in the vaginal microbiome62
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations61
Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial60
GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap59
Targeted proteomics identifies potential biomarkers of dysglycaemia, beta cell function and insulin sensitivity in Black African men and women58
Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy58
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis58
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes58
Mortality risk for kidney transplant candidates with diabetes: a population cohort study56
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study55
Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data55
Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity55
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial54
0.70300793647766